CMS: The Clinical Trials Agency?
This article was originally published in RPM Report
Executive Summary
Drug and biotech companies are getting nervous that CMS is creeping into the clinical trials business as cost of novel agents becomes a bigger issue.
You may also be interested in...
Reacting to the CATT Study: Will Makena Make a Difference?
The long awaited head-to-head trial of Avastin vs. Lucentis in macular degeneration has finally reported results. It pits a $1,500 a dose therapy against a $50, unapproved alternative that most providers think is just as good. We just had that debate over Makena. Recent comments by FDA’s top drug review official suggest there may be another connection.
Straight Talk About Cancer Drug Coverage
CMS’ coverage of cancer drugs isn’t as automatic as you think. Here’s how the Medicare agency sees it.
De-linking Coverage from Comparative Effectiveness Research
Key Republican lawmakers who could play a role in a compromise over health reform have come out strongly against comparative effectiveness research. Senate Finance Committee Chairman Baucus has been listening and is taking opposition seriously.